Ipamorelin vs CJC-1295 (no DAC)

Ipamorelin

A selective ghrelin-receptor agonist that triggers a GH pulse without raising cortisol or prolactin — the property that made it the default GHRP and pushed the older, dirtier GHRPs to the margins.

Best for

Best as the ghrelin-receptor pulse in a stack; on its own it amplifies GH pulses but does not raise baseline much.

CJC-1295 (no DAC)

A short-acting GHRH analogue — the GH pulse it produces is sharp, brief, and very close to what the pituitary does on its own. Stabilised against rapid breakdown, but without the albumin-binding modification that turns it into the long-acting DAC version.

Best for

Best as the GHRH half that lifts the overall GH signal; weaker alone than paired.

Ipamorelin

Original pharmacology work by Raun and colleagues (1998) established the GH-selectivity profile — the absence of cortisol and prolactin lift is what differentiates this peptide from the older GHRPs and the data on that point is reproducible. Long-term outcome trials in healthy adults are not the literature's strong suit. The pulse pharmacology is tight; the chronic body-recomp evidence is anecdotal-plus-mechanism rather than RCT-based.

CJC-1295 (no DAC)

The pulse-amplification pharmacology is well-characterised in short human studies — Teichman and colleagues (2006) is the canonical reference and the half-life and pulse-shape data is solid. What is missing is long-term outcome data in healthy adults. The chronic safety profile is reassuring by absence of major signals across two decades of grey-market use, but absence of signal is not the same as a chronic safety trial.